Roger Stein: A bold new way to fund drug research
Roger Stein - Financial management expert
Roger Stein wants to bring financial engineering to the world of drug funding. Full bio
that actually touches everybody.
about a one in three chance
we think about raising money
for Financial Engineering at MIT,
his own bits of research,
something we could do.
how to make a cancer drug.
of other things gets done.
the drug to healthy people
to see if the drug's effective,
give it to people with cancer
test it on a very large sample,
is what the right dose is, and also,
come out the other side.
you have one of the blue ones.
them as financial assets?"
structures and all that,
but in order to make it work,
called the Valley of Death
you can't get to the later stages.
but now we need a lot of capital,
Philanthropies don't have it.
get people in the capital markets,
a next phase of approval,
fund the next round of trials.
about five to eight percent,
about a 12-percent return.
who want to make those big bets
that would be interested in that.
in the academic press.
just make people aware of it, though.
took all of our computer code
to see if this would work.
and see how it would work.
the world to fund this stuff?
more than just money that's required.
people to get involved,
the different things that could go wrong.
this that might get in the way?
a work stream on credit risk?
on the regulatory aspects?
the summer, this past summer.
that we thought would be important,
and heard the reports
and they talked about it.
it was the summertime --
About the speaker:Roger Stein - Financial management expert
Roger Stein wants to bring financial engineering to the world of drug funding.
Why you should listen
Roger Stein is a senior lecturer in finance at MIT's Sloan School of Management and a research affiliate at the MIT Laboratory for Financial Engineering. He is also the former chief analytics officer at State Street Global Exchange. He has been working in risk modeling and financial prediction for almost 25 years; his products and services are used widely in industry and have become benchmarks in banking and finance. With MIT colleagues, he is currently collaborating on a new model that uses modern risk management methods and financial engineering techniques to change the way new drug research is funded.
Previously he was managing director of research and academic relations globally for Moody’s Corporation, and prior to that was president of Moody’s Research Labs. He has a Ph.D. from New York University, has coauthored two full-length texts on applied analytics, and has written more than 50 academic articles and papers. He has also been practicing Aikido since 1980.
Roger Stein | Speaker | TED.com